U.S. Markets closed

Spectrum Pharmaceuticals, Inc. (SPPI)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
8.1200+0.0800 (+0.9950%)
At close: 4:00PM EDT
People also watch
KERXVNDARIGLOREXPGNX

Spectrum Pharmaceuticals, Inc.

11500 South Eastern Avenue
Suite 240
Henderson, NV 89052
United States
702-835-6300
http://www.sppirx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees227

Key Executives

NameTitlePayExercisedAge
Dr. Rajesh C. Shrotriya M.D.Chairman and Chief Exec. Officer2.15MN/A73
Mr. Joseph W. TurgeonPres and Chief Operating Officer1.03MN/A59
Mr. Kurt A. GustafsonChief Financial Officer, Principal Accounting Officer and Exec. VP857.16kN/A49
Mr. Shiv KapoorVP of Strategic Planning & Investor RelationsN/AN/AN/A
Mr. Bimal R. ShahVP of Corp. and Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Corporate Governance

Spectrum Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.